Caveolin-1 and prostate cancer progression

Advances in Experimental Medicine and Biology

Volumn 729, Issue , 2012, Pages 95-110

  Freeman, Michael R ^a,b   Yang, Wei ^a,b   Di Vizio, Dolores ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CAVEOLIN 1; CELL PROTEIN; EZETIMIBE;

ANDROGEN GENE; ANDROGEN RELEASE; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CAVEOLIN 1 GENE; DOWN REGULATION; DRUG EFFECT; EVIDENCE BASED MEDICINE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; INTRACELLULAR SIGNALING; LIPID RAFT; MOLECULAR DYNAMICS; MOLECULAR EVOLUTION; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; STROMA CELL; TUMOR GENE;

ANDROGENS; ANIMALS; CAVEOLIN 1; DISEASE PROGRESSION; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STROMAL CELLS;

EID: 84859797899     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-1222-9_7     Document Type: Article

References (109)

1. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatc carinoma of the prostate. J Urol 1941; 168:9-12.
2. AttardO, ReidAH, Yap TA et al. Phase I cinicaltrial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration- resistantprostate cancer commonly remabs hormone driven. J Cib Oncol 2008; 26:4563-4571.
3. Attar RM, Takimoto CH, Gottardis MM. Castration-resistant prostate cancer: Locking up the molecular escape routes. Clin Cancer Res 2009; 15:3251-3255.
4. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: Current status and future prospects. Prostate 2004; 61:332-353.
5. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004; 25:276-308.
6. Chmelar R, Buchanan U, Need EF et al. Androgen receptor coregulator and their involvement in the development and progression of prostate cancer. Tnt J Cancer 2007; 120:719-733.
7. Fu M, Rao M, Wang C et al. Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol 2003; 23:8563-8575.
8. Hu YC, Yeh S, Yeh SD et al. Functional domain and motif analyses ofandrogen receptor coregulator ARA7O and its differential expression in prostate cancer. J Biol Chem 2004; 279:33438-33446.
9. Linja MJ, Porkka KP, Kang Z et al. Expression of androgen receptor coregulators in prostate cancer. Clin Cancer Res 2004; 10:1032-1040.
10. Linja MJ, Savinainen KJ, Saramaki OR et al. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001; 61:3550-3555.
11. Koivisto PA, Rantala I. Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer. J Pathol 1999; 187:237-241.
12. Haapala K, Kuukasjarvi T, Hyytinen E et al. Androgen receptor amplification is associated with increased cell proliferation in prostate cancer. Hum Pathol 2007; 3 8:474-478.
13. Edwards J, Krishna NS, Grigor KM et al. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003; 89:552-556.
14. Ford OH, 3rd, Gregory CW, Kim D et al. Androgen receptor gene amplification and protein expression in recunent prostate cancer. J Urol 2003; 170:1817-1821.
15. Koivisto P, Kononen J, Palmberg C et al. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997; 57:314-319.
16. Visakorpi T, Hyytinen E, Koivisto P et al. Invivo amplification of the androgenreceptor gene andprogression of human prostate cancer. Nat Genet 1995; 9:401-406.
17. Zhau HY, Chang SM, Chen BQ et al. Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci USA 1996; 93:15152-15157.
18. Magi-Galluzzi C, Xu X, Hlatky Let al. Heterogeneity of androgen receptor content in advanced prostate cancer. Mod Pathol 1997; 10:839-845.
19. Niu Y, Altuwaijri S, Lai KP et al. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci USA 2008; 105:12182-12187.
20. Niu Y, Altuwaijri S, Yeh S et al. Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proc Natl Acad Sci USA 2008; 105:12188-12193.
21. Bergerat JP, Ceraline J. Pleiotropic functional properties of androgen receptor mutants in prostate cancer. Hum Mutat 2009; 30:145-157.
22. Li W, Cavasotto CN, Cardozo T et al. Androgen receptor mutations identified in prostate cancer and androgen insensitivity syndrome display abenantART-27 coactivator function. Mol Endocrinol 2005; 19:2273-2282.
23. Yeh S, Lin HK, Kang HY et al. From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 1999; 96:5458-5463.
24. Kang HY, Lin HK, Hu YC et al. From transforming growth factor-beta signaling to androgen action: Identification of Smad3 as an androgen receptor coregulator in prostate cancer cells. Proc Natl Acad Sci USA 2001; 98:3018-3023.
25. Nickerson T, Chang F, Lorimer D et al. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 2001; 6 1:6276-6280.
26. Yang L, Xie S, Jamaluddin MS et al. Induction of androgen receptor expression by phosphatidylinositol 3-kinase Aid downstream substrate, FOXO3a and their roles in apoptosis of LNCaP prostate cancer cells. J Biol Chem 2005; 280:33558-33565.
27. Yang L, Wang L, Lin HK et al. Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3 and MAPK, three ditinct signal pathxay in protate cancer cells. Biochem Biophys Res Commun 2003; 305:462-469.
28. Plymate SR, Haugk K, Colemanlet al An antibodytargeting the type Iinsulin-like growth factorreceptor enhances the castration-induced response in androgen-dependent prostate cancer. Clin Cancer Res 2007; 13:6429-6439.
29. Montgomery RB, Mostaghel EA, Vessella R et al. Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 2008; 68:4447-4454.
30. Locke JA, Fazli L, Adomat H et al. A novel communication role for CYP17A1 in the progression of castration-resistant prostate cancer. Prostate 2009; 69:928-937.
31. Locke JA, Guns ES, Lubik AA et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008; 68:6407-6415.
32. Lee MS, Igawa T, Lin MF. Tyrosine-3 17 of p52(Shc) mediates androgen-stimulated proliferation signals in human prostate cancer cells. Oncogene 2004; 23 :3048-3058.
33. Mellinghoff IK, Vivanco I, Kwon Aet al. HER2 neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 2004; 6:517-527.
34. Wu JD, Haugk K, Woodke Let al. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem 2006; 99:392-401.
35. Lu ML, Schneider MC, Zheng Yet al. Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation. J Biol Chem 2001; 276:13442-13451.
36. Lingwood D, Simons K. Lipid rafis as a membrane-organizing principle. Science 2010; 327:46-50.
37. Freeman MR, Cinar B, Lu ML. Membrane rafis as potential sites of nongenomic hormonal signaling in prostate cancer. Trends Endocrinol Metab 2005; 16:273-279.
38. Haas D, White SN, Lutz LB et al. The modulator of nongenomic actions of the estrogen receptor (MNAR) regulates transcription-independent androgen receptor-mediated signaling: Evidence thatMNAR participates in G protein-regulated meiosis in Xenopus laevis oocytes. Mol Endocrinol 2005; 19:2035-2046.
39. Pedram A, Razandi M, Samson RC et al. A conserved mechanism for steroid receptor translocation to the plasma membrane. J Biol Chem 2007; 282:22278-22288.
40. Couet J, Sargiacomo M, Lisanti MP. Interaction of a receptor tyrosine kinase, EOF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine threonine kinase activities. J Biol Chem 1997; 272 :30429-3043 8.
41. Vihanto MM, Vindis C, Djonov Vet al. Caveolin-1 is required for signaling and membrane targeting of EphBl receptor tyrosine kinase. J Cell Sci 2006; 119:2299-2309.
42. Sen A, O'Malley K, Wang Z et al. Paxillin regulates androgen-and epidermal growth factor-induced MAPK signaling and cell proliferation in prostate cancer cells. J Biol Chem 2010; 285(37):28787-95.
43. Migliaccio A, Varricchio L, Dc Falco Aet al. Inhibition of the SH3 domain-mediated binding of Src to the androgen receptor and its effect on tumor growth. Oncogene 2007; 26:6619-6629.
44. Migliaccio A, Castoria G, Di Domenico M et al. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J 2000; 19:5406-5417.
45. Shatkina L, Mink S, Rogatsch H et al. The cochaperone Bag-iL enhances androgen receptor action via interaction with the NH2-terminal region of the receptor. Mol Cell Biol 2003; 23:7189-7197.
46. Cheung-FlynnJ, Prapapanich V, Cox MB et al. Physiologicalrole for the cochaperone FKBP52 in androgen receptor signaling. Mol Endocrinol 2005; 19:1654-1666.
47. Zoubeidi A, Zardan A, Beraldi E et al. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res 2007; 67:10455-10465.
48. Razandi M, Pedram A, Levin ER. Heat shock protein 27 is required for sex steroid receptor trafucking to and functioning at the plasma membrane. Mol Cell Biol 2010; 30:3249-3261.
49. Yang O, Truong LD, Wheeler TM et al. Caveolin-1 expression in clinically confined human prostate cancer: A novel prognostic marker. Cancer Res 1999; 59:57 19-5723.
50. Yang W, Di Vizio D, Kirchner M et al. Proteome scale characterization of human 5-acylated proteins in lipid rafi-enriched and nonrafi membranes. Mol Cell Proteomics 2010; 9:54-70.
51. Aronica SM, Kraus WL, KatzenellenbogenB S. Estrogen actionviathe cAMP signaling pathway: Stimulation ofadenylate cyclase andcAMP-regulated gene transcription. Proc Natl Acad Sci USA 1994; 91:8517-8521.
52. Whang YE, Wu X, Suzuki H et al. Inactivation of the tumor suppressor PTEN MMAC 1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 1998; 95:5246-5250.
53. WuX, Senechal K, Neshat MS et al. The PTEN MMAC 1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase Akt pathway. Proc Natl Acad Sci USA 1998; 95:15587-15591.
54. CinarB, MukhopadhyayNK, Meng U et al. Phosphoinositide 3-kinase-independent nongenomic signals transit from the androgen receptor to Aktl inmembrane raft microdomains. J Biol Chem 2007; 282:29584-29593.
55. Li L, Ren CH, Tahir SA et al. Caveolin-1 maintains activatedAkt inprostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine threonine protein phosphatases PP 1 and PP2A. Mol Cell Biol 2003; 23:9389-9404.
56. Caselli A, Mazzinghi B, Camici G et al. Some protein tyrosine phosphatases target in part to lipid rafis and interact with caveolin-1. Biochem Biophys Res Commun 2002; 296:692-697.
57. Yang O, Truong LD, Timme TL et al. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 1998; 4:1873-1880.
58. Tahir SA, Yang O, Ebara S et al. Secreted caveolin-1 stimulates cell survivallclonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 2001; 61:3882-3885.
59. Tahir SA, Frolov A, Hayes TO et al. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res 2006; 12:4872-4875.
60. Di Vizio D, Sotgia F, Williams TM et al. Caveolin-1 is required for the upregulation of fatty acid synthase (FASN), a tumor promoter, during prostate cancer progression. Cancer Biol Ther 2007; 6:1263-1268.
61. Di Vizio D, Adam RM, Kim J et al. Caveolin-1 interacts with a lipid rafi-associated population of fatty acid synthase. Cell Cycle 2008; 7:2257-2267.
62. Yang U, Addai J, Wheeler TM et al. Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis. Hum Pathol 2007; 38: 1688-1695.
63. Yang O, Timme TL, Frolov Aet al. Combined c-Myc and caveolin-1 expressionin human prostate carcinoma predicts prostate carcinoma progression. Cancer 2005; 103:1186-1194.
64. Yang O, Addai J, Ittmann M et al. Elevated caveolin-1 levels in African-American versus white-American prostate cancer. Clin Cancer Res 2000; 6:3430-3433.
65. Williams TM, Hassan US, Li Jet al. Caveolin-1 promotes tumor progression in an autochthonous mouse model ofprostate cancer: Genetic ablation of Cay-i delays advanced prostate tumor development in tramp mice. J Biol Chem 2005; 280:25134-25 145.
66. Williams TM, Medina F, Badano I et al. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cay-i in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem 2004; 279:51630-51646.
67. Williams TM, Cheung MW, Park DS et al. Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice. Mol Biol Cell 2003; 14:1027-1042.
68. Nasu Y, Timme TL, Yang O et al. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat Med 1998; 4:1062-1064.
69. Li L, Yang O, Ebara S et al. Caveolin-1 mediates testosterone-stimulated survivallclonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res 2001; 61:4386-4392.
70. Timme TL, Goltsov A, Tahir S et al. Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis. Oncogene 2000; 19:3256-3265.
71. Park DS, Woodman SE, SchubertW et al. Caveolin-1 3 double-knockout mice are viable, but lack both muscle and non Muscle caveolae and develop a severe cardiomyopathi cphenotype. Ani J Pathol 2002; 160:2207-2217.
72. Schaffuer CP, Gordon HW. The hypocholesterolemic activity of orally administered polyene macrolides. Proc Natl Acad Sci USA 1968; 61:36-41.
73. SchaffuerCP. Prostatic cholesterol metabolism:regulation and alteration. Prog Clin Biol Res 1981; 75A:279-324.
74. Solomon KR, Pelton K, Boucher K et al. Ezetimibe is an inhibitor of tumor angiogenesis. Am J Pathol 2009; 174:1017-1026.
75. Freeman MR, Solomon KR. Cholesterol and prostate cancer. J Cell Biochem 2004; 91:54-69.
76. Murtola TJ, Tammela IL, Maattanen L et al. Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. Tnt J Cancer 2010; 127(7): 1650-9.
77. Platz EA, Till C, Goodman PJ et al. Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prey 2009; 18:2807-2813.
78. Platz EA, Clinton SK, Giovannucci E. Association between plasma cholesterol and prostate cancer in the PSA era. Tnt J Cancer 2008; 123:1693-1698.
79. Platz EA, Leitzmann MF, Visvanathan K et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006; 98:1819-1825.
80. Zhang Y, Calvo E, Martel C et al. Response of the adipose tissue transcriptome to dihydrotestosterone in mice. Physiol Genomics 2008; 35:254-26 1.
81. Chauvin TR, Griswold MD. Androgen-regulated genes in the murine epididymis. Biol Reprod 2004; 71:560-569.
82. Swinnen JV, Heemers H, van de Sande I et al. Androgens, lipogenesis and prostate cancer. J Steroid Biochem Mol Biol 2004; 92:273-279.
83. Kim J, Adam RM, Solomon KR et al. Involvement of cholesterol-rich lipid rafis in interleukin-6-induced neuroendocrine differentiation of LNCaP prostate cancer cells. Endocrinology 2004; 145:613-619.
84. Adam RM, Mukhopadhyay NK, Kim Jet al. Cholesterol sensitivity of endogenous and myristoylated Akt. Cancer Res 2007; 67:6238-6246.
85. Zhuang L, Lin J, Lu ML et al. Cholesterol-rich lipid rafis mediate akt-regulated survival in prostate cancer cells. Cancer Res 2002; 62:2227-223 1.
86. Zhuang L, Kim J, Adam RM et al. Cholesterol targeting alters lipid rafi composition and cell survival in prostate cancer cells and xenografls. J Clin Invest 2005; 115:959-968.
87. Liu L, Brown D, McKee M et al. Deletion of Cavin/PTRF causes global loss of caveolae, dyslipidemia and glucose intolerance. Cell Metab 2008; 8:310-317.
88. Hill MM, Bastiani M, Luetterforst R et al. PTRF-Cavin, a conserved cytoplasmic protein required for caveola formation and function. Cell 2008; 132:113-124.
89. Liu L, Pilch PF. A critical role of cavin (polymerase I and transcript release factor) in caveolae formation and organization. J Biol Chem 2008; 283:4314-4322.
90. Gould ML, Williams G, Nicholson HD. Changes in caveolae, caveolin and polymerase 1 and transcript release factor (PTRF) expression in prostate cancer progression. Prostate 2010; 70(15):1609-21.
91. Hayer A, Stoeber M, Bissig C et al. Biogenesis of caveolae: Stepwise assembly of large caveolin and cavin complexes. Trafuc 2010; 11:361-382.
92. Frank PG, Pavlides S, Cheung MW et al. Role of caveolin-1 in the regulation of lipoprotein metabolism. Am J Physiol Cell Physiol 2008; 295:C242-248.
93. Razani B, Combs TP, Wang XB et al. Caveolin-1-deficient mice are lean, resistant to diet-induced obesity and show hypertriglyceridemia with adipocyte abnormalities. J Biol Chem 2002; 277:8635-8647.
94. Tahir SA, Ren C, Timme TL et al. Development of an immunoassay for serum caveolin-1: A novel biomarker for prostate cancer. Clin Cancer Res 2003; 9:3653-3659.
95. Tahir SA, YangG, GoltsovAA et al. Iumorcell-secretedcaveolin-1 has proangiogenic activities in prostate cancer. Cancer Res 2008; 68:731-739.
96. Bartz R, Zhou J, Hsieh JT et al. Caveolin-1 secreting LNCaP cells induce tumor growth of caveolin-1 negative LNCaP cells in vivo. Tnt J Cancer 2008; 122:520-525.
97. Di Vizio D, Kim J, Hager MH et al. Oncosome formation in prostate cancer: Association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res 2009; 69:5601-5609.
98. Dakhova O, Ozen M, Creighton CJ et al. Global gene expression analysis of reactive stroma in prostate cancer. Clin Cancer Res 2009; 15:3979-3989.
99. Tuxhorn JA, Ayala GE, Smith MJ et al. Reactive stroma inhumanprostate cancer: Induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 2002; 8:29 12-2923.
100. Mercier I, Casimiro MC, Wang C et al. Humanbreast cancer- associatedfibroblasts (CAFs) show caveolin-1 downregulationandRB tumor suppressor functional inactivation: Implications for theresponse tohormonal therapy. Cancer Biol Ther 2008; 7:1212-1225.
101. Josson S, Matsuoka Y, Chung LW et al. Tumor-stroma co-evolution in prostate cancer progression and metastasis. Semin Cell Dcv Biol 2010; 21:26-32.
102. Vanpoucke G, On B, Grace OC et al. Transcriptional profiling of inductive mesenchyme to identify molecules involved in prostate development and disease. Genome Biol 2007; 8:R213.
103. Galbiati F, Volonte D, Engelman JA et al. Targeted downregulation of caveolin-1 is sufucient to drive cell transformation and hyperactivate the p42 44 MAP kinase cascade. EMBO J 1998; 17:6633-6648.
104. Engelman JA, Wykoff CC, Yasuhara S et al. Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. J Biol Chem 1997; 272:16374-16381.
105. Koleske AJ, Baltimore D, Lisanti MP. Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Nati Acad Sci USA 1995; 92:1381-1385.
106. SotgiaF, Del Galdo F, Casimiro MC et al. Caveolin-1 null mammary stromalfibroblasts share characteristics with human breast cancer-associated fibroblasts. Am J Pathol 2009; 174:746-761.
107. Witkiewicz AK, Dasgupta A, Sotgia F et al. An absence of stromal caveolin-1 expression predicts early tumor recunence and poor clinical outcome in human breast cancers. Am J Pathol 2009; 174:2023-2034.
108. Di Vizio D. Morello M. Sotgia F et al. An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation. Cell Cycle 2009; 8:2420-2424.
109. Yang F, Tuxhorn JA, Ressler SJ et al. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res 2005; 65:8887-8895.